Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Wirecath

Financiado

Cerrado

Novel Catheter for the Diagnosis of Cardiovascular Disease

Cavis Technologies has an objective to clinically validate and commercialise Wirecath – its novel medical device for assessing severity of narrowings in the coronary arteries and myocardial disease. It has the potential to substan... ver más

31/01/2020

CAVIS TECHNOLOGIES

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

CAVIS TECHNOLOGIES AB No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-01-31

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

CAVIS TECHNOLOGIES

50.00K€ | Lider

ROLABO OUTSOURCING

765.98K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CNAP HD Continuous Non invasive diagnosis of Arterial Pressure and H... 71K€ Cerrado

PID2021-122518OB-I00 MODELOS COMPUTACIONALES PARA LA EVALUACION Y TRATAMIENTO DE... 151K€ Cerrado

V-LAP A revolutionary direct daily heart monitoring platform for... 3M€ Cerrado

HEART DEVICE IMAGING Advancing percutaneous heart valve repair in children throug... 171K€ Cerrado

V-LAP Saving millions of lives by enabling an effective treatment... 71K€ Cerrado

STRICT SN The first blood biomarker to accurately STratify mortali... 120K€ Cerrado

Duración del proyecto: 6 meses Fecha Inicio: 2019-07-11
Fecha Fin: 2020-01-31

Líder del proyecto

CAVIS TECHNOLOGIES AB No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cavis Technologies has an objective to clinically validate and commercialise Wirecath – its novel medical device for assessing severity of narrowings in the coronary arteries and myocardial disease. It has the potential to substantially reduce management costs in cardiovascular disease by improving its diagnosis, and thus, increasing opportunity for timely prevention of disease progression and its severe complications, such as angina, shortness of breath and heart attack. Wirecath has several premium features over competing solutions. These are an unique high accuracy, superior manoeuvrability and cost-effectiveness. Its simple and robust design bases on a unique position of pressure sensor and resistance to hydrostatic error, that standard pressure wires are liable to. Given that hydrostatic error often leads to misdiagnosis of the coronary artery disease severity, Wirecath optimises diagnostic accuracy and offers long-lasting benefits to patients, cardiologists and healthcare providers. The unique accuracy allow new methods to be developed, applicable to another large patient group that has non-obstructive CAD, with no good diagnosis tools available today. With this project, Cavis intends to support 2019’s commercial launch of Wirecath and plan further product development and large-scale clinical evaluation studies that will follow the first-in-man study planned for 2019. Cavis’ current research and development activities are supported by investment from shareholders and numerous innovation grants. Cavis plans to apply for SME Instrument Phase 2 funding to perform clinical studies that will build trust in its unique features and increase its commercial value. With 1.9 million deaths a year, cardiovascular diseases are the leading cause of death in the EU and place a considerable burden on healthcare systems and government budgets. Prevention and treatment of various cardiovascular diseases, is of a high strategic priority.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores